Browsing by Subject "Oncology"
Now showing items 1-20 of 37
-
Article
Anxiety, depression and defense mechanisms associated with treatment decisional preferences and quality of life in non-metastatic breast cancer: A 1-year prospective study
(2013)Objective: Treatment decisional preferences impact breast cancer patients' health-related quality of life (HRQoL) and may relate to psychological variables, although many aspects of this relationship remain unknown. This ...
-
Article
Brain metastasis of unknown primary: A diagnostic and therapeutic dilemma
(2005)The diagnosis of a brain metastasis is usually made during the routine follow up examinations of patients with known cancer, who are under the care of oncology departments. The involvement of the neurosurgeon depends on ...
-
Article
Cationic nanoparticles have superior transvascular flux into solid tumors: Insights from a mathematical model
(2013)Despite their great promise, only a few nanoparticle formulations have been approved for clinical use in oncology. The failure of nano-scale drugs to enhance cancer therapy is in large part due to inefficient delivery. To ...
-
Article
Computer-aided detection of breast cancer nuclei
(1997)A computer-aided detection system for tissue cell nuclei in histological sections is introduced and validated as part of the Biopsy Analysis Support System (BASS). Cell nuclei are selectively stained with monoclonal ...
-
Article
Decision-making preferences and information needs among Greek breast cancer patients
(2011)Objectives: We aimed at assessing Greek breast cancer patients' preferences for participation in treatment decision making and their information needs. Methods: In a cross-sectional study, 329 breast cancer patients were ...
-
Article
Design considerations for nanotherapeutics in oncology
(2015)Nanotherapeutics have improved the quality of life of cancer patients, primarily by reducing the adverse effects of chemotherapeutic agents, but improvements in overall survival are modest. This is in large part due to the ...
-
Conference Object
Design rules for cancer nanomedicines
(Affiliation: Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, CyprusAffiliation: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesCorrespondence Address: Stylianopoulos, T.Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus, 2012)The use of nanotechnology has offered new hope for cancer detection, prevention and treatment. Nanoparticle formulations are advantageous over conventional chemotherapy because they can incorporate multiple diagnostic and ...
-
Article
Diffuse large cell lymphomas: Identification of prognostic factors and validation of the international non-Hodgkin's Lymphoma Prognostic Index
(1998)Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently ...
-
Article
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group
(2003)There is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part ...
-
Article
-
Article
-
Article
-
Article
-
Article
The ESMO guideline strategy: An identity statement and reflections on improvement
(2015)Guidelines should provide recommendations on the optimal management of a patient in specific clinical circumstances based on the scientific evidence. ESMO, as Europe's leading society in medical oncology produces a range ...
-
Article
-
Article
-
Article
Forty years experience of treating cancer of unknown primary
(2007)Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists ...
-
Article
-
Article
-
Article
Heterogeneity in cancer guidelines: Should we eradicate or tolerate?
(2008)Background: Heterogeneity in aspects of development, structure and context of oncology guidelines was not evaluated. We analysed and critically examined its implications. Materials and methods: Nine cancer clinical practice ...